MAbxience acquired the second 4,000L Custom Single Run (CSR®) bioreactor from ABEC to to strengthen the manufacturing capacity of its site located in León, Spain
BETHLEHEM, Pennsylvania, June 02, 2022-(BUSINESS WIRE)-ABEC, a global provider of engineering solutions and services for biotech manufacturing, announces that mAbxience will install an additional ABEC 4,000L CSR bioreactor at the BPF site its in León, Spain. Following the delivery of the first 4,000L CSR bioreactor in 2021, mAbxience is once again maintaining ABEC’s innovative single-use technology to increase its CDMO business and capacity.
This press release contains multimedia elements. See the full press release here: https://www.businesswire.com/news/home/20220602005041/fr/
In April 2022, and after being notably approved in Europe, Canada and Japan, the United States Food and Drug Administration (FDA) approved a biological license application (BLA) for bevacizumab-maly, developed by mAbxience and the third biosimilar approved. in the United States. Combining innovation and cutting-edge technology with R&D, mAbxience is focused on improving patient access to life-saving treatments. With this additional 4,000L CSR bioreactor, mAbxience will benefit from increased cell culture productivity and increased scalability of the process transfer.
“MAbxience’s continued growth in the biosimilars market demonstrates the value of our strategic partnerships, such as the one at ABEC“, said Emmanuelle Lepine, CEO of mAbxience. “As we look to the future of healthcare, we are excited to be ahead of sustainable practices that will improve access to essential medicines.”
“ABEC continues to lead the industry in bringing enhanced scale and productivity to single -use manufacturing,” said Scott Pickering, Chairman and CEO of ABEC. “We are proud to continue to support mAbxience’s growth with our innovative CSR technology.”
Since 1974, ABEC has been a world leader in engineering solutions and services for the manufacturing sector of the biotech industry. Most pharmaceutical and biotechnology companies in the world are ABEC customers. Many advanced treatments have been developed using processes and equipment designed, manufactured, installed and serviced by ABEC. ABEC’s exceptional value is based on its long history, comprehensive in-house capabilities, personalized and flexible approach, and long-term credibility. Whether expanding or enhancing existing capabilities or facilities, ABEC’s turnkey solutions and support services reduce total cost and time to market while ensuring maximum productivity. For more information about ABEC, visit abec.com, contact us at firstname.lastname@example.org, and follow us on LinkedIn.
MAbxience is a fully integrated international biopharmaceutical company specializing in the development, manufacturing and marketing of monoclonal antibodies and CDMO services, and part of the pharmaceutical group Insud Pharma. Created in 2010, mAbxience operates three innovative sites, located in Spain and Argentina. MAbxience works with several biopharmaceutical products covering a variety of therapeutic areas. In 2014, mAbxience launched its first biosimilar, rituximab (product code: RTXM83-MB01), which is now approved and placed in several markets around the world. Its second product, bevacizumab (product code: BEVZ92-MB02), was developed and launched in Latin America in 2016. mAbxience focuses on the quality, safety and efficacy of its drugs. The mAbxience team works for patient care and for expanded access to its biopharmaceutical drugs on a global scale. The Society’s mission is to improve patient access to high-quality treatments for conditions requiring expensive drugs and to positively contribute to the maintenance of health care systems. Insud Pharma Group was created by Dr Hugo Sigman and Dr Silvia Gold, with over 40 years of experience in the pharmaceutical sector and employing more than 6,000 people worldwide.
The text of the press release resulting from a translation should not be considered official. The only true version of the press release is the press release in its original language. The translation always has to be compared to the source text, which will set a precedent.
Check out the source version at businesswire.com: https://www.businesswire.com/news/home/20220602005041/en/
Susan Cooper-Curcio, Director of Marketing, +1 (610) 861 4666, email@example.com
Lara Recuero, firstname.lastname@example.org